Tofacitinib citrate (TWi Biotechnology)

枸橼酸托法替布 (TWi Biotechnology)

Report date: 2025/12/12 11:45:49

Base Information

Drug NameTofacitinib citrate (TWi Biotechnology)
Drug Alias NameAC-1101IMG 003
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK1 inhibitorsTyrosine-protein kinase JAK2 inhibitorsTyrosine-protein kinase JAK3 inhibitors
TargetsTyrosine-protein kinase JAK1Tyrosine-protein kinase JAK2Tyrosine-protein kinase JAK3
Therapy Area/IndicationsGranuloma Annulare
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesTwi Biotechnology Inc
China Registration ClassN/A

Develop Information

Active CompaniesTwi Biotechnology Inc
Inactive CompaniesN/A
Active IndicationsGranuloma Annulare
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG